Development of a prototype of a theranostic system based on silica nanoparticles with immobilized fluorescent dyes and VEGF targeting ligand.

Yu. V. Cheburkin, G. A. Shulmeister, A. B. Bondarenko, A. V. Chistyakova, D. V. Korolev
{"title":"Development of a prototype of a theranostic system based on silica nanoparticles with immobilized fluorescent dyes and VEGF targeting ligand.","authors":"Yu. V. Cheburkin, G. A. Shulmeister, A. B. Bondarenko, A. V. Chistyakova, D. V. Korolev","doi":"10.18705/2311-4495-2023-10-6-522-534","DOIUrl":null,"url":null,"abstract":"Background. Administration of certain drugs causes undesirable effects associated with the systemic effect of the active substance on the entire body. Selective targeting of the drug to the affected tissue promotes a selective increase in the concentration of the substance in the area of interest, thereby reducing the systemic effect and enhancing the local therapeutic effect.Objective. Development of a targeted delivery system for theranostic agents using recombinant human vascular endothelial growth factor type A (rhVEGF-A121) as a targeting ligand.Design and method. To create the theranostic complex, commercially available reagents were used: the recombinant protein rhVEGF-A121 (cat.#: PSG140-10, LLC CyStorLab, Skolkovo, Russia) and fumed silica Aerosil (A-200, Degussa AG, Germany). The tosyl spacer that interconnects both components was synthesized in the laboratory. Protein conjugation with fluorophores was also carried out in-house. Indocyanine green (ICG; Sigma-Aldrich, USA) and rhodamine B (JSC Lenreaktiv, St. Petersburg, Russia) were taken for immobilization.Results. In the course of the work, functionalization of silica nanoparticles (SiNPs) with a tosyl spacer was carried out, conjugates of SiNPs with rhVEGF-A121 were synthesized, and theranostic constructs based on SiNPs were obtained, including rhVEGF-A121 as a targeting ligand, and ICG/Rhodamine B as a visualizing label.Conclusion. In the presented study, a prototype of a complex for targeted delivery of a theranostic agent to tissues with an active angiogenesis process, for example, to tumor and ischemic tissues, was developed. To solve the problem, we immobilized on the surface of SiNP a recombinant protein of human vascular endothelial growth factor (rhVEGF) to use as a guide ligand. Such a synthetic construct will help to deliver diagnostic and/ or medicinal substances packed in SiNP directly to cells that overexpress extracellular specific receptors of the VEGFR family. In subsequent in vivo experiments, delivery efficiency will be assessed by tissue accumulation of the fluorophores ICG and rhodamine B, which have been conjugated to the targeting ligand protein. The physicochemical characteristics of the obtained samples were studied by the methods of spectrophotometry and dynamic light scattering.","PeriodicalId":23243,"journal":{"name":"Translational Medicine","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-01-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Translational Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.18705/2311-4495-2023-10-6-522-534","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Background. Administration of certain drugs causes undesirable effects associated with the systemic effect of the active substance on the entire body. Selective targeting of the drug to the affected tissue promotes a selective increase in the concentration of the substance in the area of interest, thereby reducing the systemic effect and enhancing the local therapeutic effect.Objective. Development of a targeted delivery system for theranostic agents using recombinant human vascular endothelial growth factor type A (rhVEGF-A121) as a targeting ligand.Design and method. To create the theranostic complex, commercially available reagents were used: the recombinant protein rhVEGF-A121 (cat.#: PSG140-10, LLC CyStorLab, Skolkovo, Russia) and fumed silica Aerosil (A-200, Degussa AG, Germany). The tosyl spacer that interconnects both components was synthesized in the laboratory. Protein conjugation with fluorophores was also carried out in-house. Indocyanine green (ICG; Sigma-Aldrich, USA) and rhodamine B (JSC Lenreaktiv, St. Petersburg, Russia) were taken for immobilization.Results. In the course of the work, functionalization of silica nanoparticles (SiNPs) with a tosyl spacer was carried out, conjugates of SiNPs with rhVEGF-A121 were synthesized, and theranostic constructs based on SiNPs were obtained, including rhVEGF-A121 as a targeting ligand, and ICG/Rhodamine B as a visualizing label.Conclusion. In the presented study, a prototype of a complex for targeted delivery of a theranostic agent to tissues with an active angiogenesis process, for example, to tumor and ischemic tissues, was developed. To solve the problem, we immobilized on the surface of SiNP a recombinant protein of human vascular endothelial growth factor (rhVEGF) to use as a guide ligand. Such a synthetic construct will help to deliver diagnostic and/ or medicinal substances packed in SiNP directly to cells that overexpress extracellular specific receptors of the VEGFR family. In subsequent in vivo experiments, delivery efficiency will be assessed by tissue accumulation of the fluorophores ICG and rhodamine B, which have been conjugated to the targeting ligand protein. The physicochemical characteristics of the obtained samples were studied by the methods of spectrophotometry and dynamic light scattering.
基于硅纳米颗粒与固定荧光染料和血管内皮生长因子靶向配体的治疗系统原型的开发。
背景。服用某些药物会产生不良反应,这与活性物质对全身的全身效应有关。将药物选择性地靶向作用于受影响的组织,可有选择性地提高相关部位的药物浓度,从而减少全身效应,增强局部治疗效果。以重组人血管内皮生长因子 A 型(rhVEGF-A121)为靶向配体,开发治疗药物靶向递送系统。为了制造治疗复合物,使用了市售试剂:重组蛋白 rhVEGF-A121(cat.#: PSG140-10,LLC CyStorLab,Skolkovo,俄罗斯)和气相二氧化硅 Aerosil(A-200,Degussa AG,德国)。连接这两种成分的甲苯基间隔物是在实验室合成的。蛋白质与荧光团的连接也是在实验室内完成的。吲哚菁绿(ICG;Sigma-Aldrich,美国)和罗丹明 B(JSC Lenreaktiv,俄罗斯圣彼得堡)被用于固定。在研究过程中,对二氧化硅纳米粒子(SiNPs)进行了甲苯基间隔物功能化,合成了硅纳米粒子与 rhVEGF-A121 的共轭物,并获得了基于硅纳米粒子的治疗构建物,其中包括作为靶向配体的 rhVEGF-A121,以及作为可视化标签的 ICG/Rhodamine B。本研究开发了一种复合物原型,用于向血管生成过程活跃的组织(如肿瘤和缺血组织)定向递送治疗剂。为了解决这个问题,我们在 SiNP 表面固定了人血管内皮生长因子(rhVEGF)的重组蛋白,作为引导配体。这种合成构建物将有助于直接向过度表达血管内皮生长因子受体家族细胞外特异性受体的细胞输送包裹在 SiNP 中的诊断和/或药物物质。在随后的体内实验中,将通过组织中与靶向配体蛋白共轭的荧光团 ICG 和罗丹明 B 的积累来评估输送效率。通过分光光度法和动态光散射法研究了所得样品的理化特性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信